MONTREAL, Nov. 27 /PRNewswire-FirstCall/ - CryoCath Technologies Inc.(TSX: CYT), the global leader in cryotherapy products to treat cardiacarrhythmias, today announced that Jan Keltjens, President and CEO of CryoCath,will present at both the Piper Jaffray 19th Annual Health Care Conference andthe BMO Focus on Healthcare Conference. The Piper Jaffray Conferencepresentation will take place today at 1:50 pm ET at the Pierre Hotel in NewYork City and the BMO Conference will take place on Wednesday, December 5 at2:00 pm ET at the Millenium Broadway Hotel in New York City. Both events willfeature a market outlook and discuss some recent events and upcomingmilestones, including the STOP AF IDE Trial for Arctic Front(R), the Company'sminimally invasive cryo-balloon catheter designed specifically to treatparoxysmal atrial fibrillation.
The BMO Focus on Healthcare Conference will be accompanied by a livewebcast of Mr. Keltjens' presentation, available at www.cryocath.com.
CryoCath - www.cryocath.com - is a medical technology company that leadsthe world in cryotherapy products to treat cardiovascular disease. With apriority focus on providing physicians with a complete solution of catheterproducts to treat cardiac arrhythmias, CryoCath has multiple products approvedin the U.S., across Europe and several ROW countries. The Company isdeveloping additional products to expand its pipeline of products to treatcardiac arrhythmias.
This press release includes "forward-looking statements" that are subjectto risks and uncertainties, including with respect to the timing of regulatorytrials and their outcome. For information identifying legislative orregulatory, economic, climatic, currency, technological, competitive and otherimportant factors that could cause actual results to differ materially fromthose anticipated in the forward looking statements, see CryoCath's annualreport available at www.sedar.com under the heading Risks and Uncertainties inthe Management's Discussion and Analysis section.
SOURCE CryoCath Technologies Inc.